An association study between genetic polymorphisms related to lipoprotein-associated phospholipase A2 and coronary heart disease

LIMIN XU1*, JIANQING ZHOU2*, STEPHANIE HUANG3, YI HUANG1, YANPING LE1, DANJIE JIANG1, FEIMING WANG4, XI YANG2, WEIFENG XU2, XIAOYAN HUANG2, CHANGZHENG DONG1, LINA ZHANG1, MENG YE1, JIANGFANG LIAN2 and SHIWEI DUAN1

1School of Medicine, The Affiliated Hospital, Ningbo University, Ningbo, Zhejiang 315211; 2Ningbo Medical Center, Lihuili Hospital, Ningbo, Zhejiang 315041, P.R. China; 3Department of Medicine, University of Chicago, Chicago, IL 60637, USA; 4Zhejiang Zhenhai Middle School, Ningbo, Zhejiang 315200, P.R. China

Received December 8, 2012; Accepted January 14, 2013

DOI: 10.3892/etm.2013.911

Abstract. Previous genome-wide association studies (GWAS) have revealed seven single nucleotide polymorphisms (SNPs) that affect lipoprotein-associated phospholipase A2 (Lp-PLA2) activity or levels in American and European individuals. A total of 290 coronary heart disease (CHD) patients, 198 non-CHD patients and 331 unrelated healthy volunteers were recruited for the present case-control study of Han Chinese. Four SNPs (rs964184 of ZNF259, rs7528419 of CELSR2 and rs7756935 and rs1805017 of PLA2G7) were shown to be significantly associated with CHD. The rs964184-G allele of the ZNF259 gene was identified as a risk factor of CHD in females (odds ratio (OR) =1.49, 95% confidence interval (CI) =1.00-2.22, P=0.05). The rs7528419-G allele of the CELSR2 gene was protective against CHD in males (OR=0.48, 95% CI=0.25-0.93, P=0.04). The other two alleles (rs7756935-C and rs1805017-A) of the PLA2G7 gene acted as protective factors against CHD in females (rs7756935-C: OR=0.59, 95% CI=0.35-1.00, P=0.05; rs1805017-A: OR=0.51, 95% CI=0.28-0.93, P=0.03).

Moreover, rs1805017 of the PLA2G7 gene was associated with the severity of CHD only in females (r²=0.02, P=0.04). We identified four Lp-PLA2-associated SNPs significantly associated with CHD in a Han Chinese population. Specifically, rs7528419 was protective factor against CHD in males, while the other two SNPs (rs7756935 and rs1805017 of the PLA2G7 gene) were protective factors against CHD in females and rs964184 of the ZNF259 gene was regarded as a risk factor for CHD in females.

Introduction

Coronary heart disease (CHD) is a dynamic inflammatory disease process caused by atherosclerosis, which is the narrowing or blockage of the coronary arteries. Atherosclerosis may eventually lead to severe events, including sudden mortality, myocardial infarction (MI) or acute coronary syndrome (ACS). These events are often dependent on inflammatory changes within the arterial walls (1).

As a biomarker of plaque inflammation and stability (2), lipoprotein-associated phospholipase A2 (Lp-PLA2) plays an important role in the progression of atherosclerosis (3). Lp-PLA2 is a pro-inflammatory enzyme that hydrolyzes oxidized phospholipids to generate lysophosphatidylcholine and oxidized fatty acids (4). This enzyme non-covalently binds to plasma lipoproteins (5). Lp-PLA2 binds with a much higher affinity to low-density lipoprotein (LDL) than to high-density lipoprotein (HDL) (5). Approximately 80% of Lp-PLA2 is attached to LDL and the rest to HDL in plasma (2). LDL cholesterol (LDL-C) has a causal role in the development of cardiovascular disease (6). Epidemiological evidence has established a strong correlation between low levels of HDL cholesterol (HDL-C) and cardiovascular events (7). A 1 mg/dl increase in HDL-C results in a 3% reduction in CHD outcomes (8). CHD subjects often have abnormal phenotypes, including high LDL-C, low HDL-C and high triglyceride (TG) concentrations (9).

A meta-analysis identified a high risk of cardiovascular events for patients with high Lp-PLA2 levels (2). Lp-PLA2 is
important for the formation of an atherosclerotic plaque and its rupture (10). Another meta-analysis of ~80,000 participants in 32 prospective studies identified that high levels of Lp-PLA₂ mass and activity are associated with a risk of CHD, stroke and cardiovascular mortality (11). Lp-PLA₂ activity has also been shown to be a predictive factor for stroke and transient ischemic attack (TIA) (12).

Grallert et al (13) identified seven Lp-PLA₂-associated single nucleotide polymorphisms (SNPs), including rs7528419 of the CELSR2 gene, rs7756935 and rs1805017 of the PLA2G7 gene, rs964184 of the ZNF259 gene, rs10846744 of the SCARBI gene, rs247616 of the cholesteryl ether transfer protein ( CETP) gene and rs6511720 of the LDL receptor (LDLR) gene. Among them, rs1805017 and rs247616 are associated with Lp-PLA₂ mass and the other five SNPs are associated with Lp-PLA₂ activity. It has been suggested that these seven SNPs play an important role in either lipid levels or CHD. However there is a lack of evidence concerning their roles in CHD in a Han Chinese population. The aim of our study was to investigate the association between the seven Lp-PLA₂-associated SNPs and CHD in Han Chinese individuals.

Materials and methods

Sample collection. A total of 488 unrelated individual inpatients were selected between May 2008 and November 2011 from Ningbo Lihuili Hospital, Zhejiang, China. Of these, 290 patients had CHD (males, 210; females, 80; age, 62.07±9.50 years) and 198 patients were non-CHD controls (males, 101; females, 97; age, 58.66±9.31 years). In addition, 331 healthy individuals from Ningbo, China were recruited as the healthy controls (males, 86; females, 245; age, 63.41±9.21 years). The patients had been examined by standardized coronary angiography according to the Seldinger method (14) and judged by at least two independent cardiologists. CHD cases (n=290) had ≥50% coronary artery occlusion of one or more of the major coronary arteries (15) or a history of prior angioplasty or coronary artery bypass surgery. Non-CHD controls (n=198) had <50% occlusion in the major coronary artery and did not have atherosclerotic vascular disease. All the samples were from Han Chinese individuals from Ningbo, China. All individuals had no cardiomyopathy or congenital heart, liver or renal disease. The blood samples of CHD cases, non-CHD controls and healthy controls were collected by the same investigators. Blood samples were collected in 3.2% citrate sodium-treated tubes and then stored at -80°C. The study protocol was approved by the Ethics Committee of Lihuili Hospital in Ningbo and informed written consent was obtained from all subjects.

SNP genotyping. Human genomic DNA was prepared from peripheral blood samples using the nuclease acid extraction automatic analyzer (Lab-Aid 820, Xiamen, China) and was quantified using the PicoGreen® dsDNA Quantification kit (Molecular Probes Inc., Eugene, OR, USA). Amplification was performed on the ABI GeneAmp® PCR System 9700 Dual 384-Well Sample Block Module (Applied Biosystems, Foster City, CA, USA). Polymerase chain reaction (PCR) was performed with an initial denaturation stage at 94°C for 15 sec, followed by 45 cycles of 94°C for 20 sec, 56°C for 30 sec and 72°C for 1 min, then a final extension for 3 min at 72°C. Primer extension genotyping was performed on the Sequenom MassARRAY iPLEX® platform (Sequenom Inc., San Diego, CA, USA) according to the manufacturer's instructions (16). The primer extension reaction included an initial denaturation stage at 94°C for 30 sec, followed by 40 cycles of amplification, including 94°C for 5 sec, 5 cycles at 52°C for 5 sec and 80°C for 5 sec, then a final extension for 3 min at 72°C. After purifying the products and transferring to a SpectroCHIP, MALDI-time-of-flight (TOF) mass spectrometry was used for SNP genotyping.

Statistical analysis. The Hardy-Weinberg equilibrium (HWE) was analyzed using Arlequin software (v3.5) (17). Genotype and allele frequencies between CHD cases and each of the two controls (non-CHD controls and healthy controls) were compared using Clump 16 software with 10,000 Monte Carlo simulations (18). The linkage disequilibrium (LD) between the two SNPs in PLA2G7 was measured by an online calculator (http://www.oege.org/software/cubex/). The odds ratio (OR) with 95% confidence interval (95% CI) were calculated using an online program (http://faculty.vassar.edu/lowry/odds2x2.html). The power of the study was estimated by the Power and Sample Size Calculation software (v3.0.43) (19). The logistic regression test between genotype and the severity of CHD was performed using R statistical software. A two-tailed P-value <0.05 was considered to indicate a statistically significant difference.

Results

HWE test. In the present study, we examined a total of seven SNPs associated with either the mass or the activity of Lp-PLA₂. We first analyzed the HWE of these SNPs in CHD cases, non-CHD controls and healthy controls. All SNPs were consistent with HWE with the exception of two SNPs (rs10846744 and rs1805017). The rs10846744 SNP of the SCARBI gene did not meet HWE in the CHD cases and in each of the two controls (P<0.001) and thus was not further analyzed. The genotype distribution of rs1805017 of the PLA2G7 gene did not meet the HWE in the non-CHD controls and in each of the two controls (P<0.001). Therefore, the association between rs1805017 and Lp-PLA₂ was only studied in females.

Genotypic and allelic analyses. The genotype and allele frequencies of six SNPs are shown in Table I. Although no significant difference was observed in the genotype level for all the SNPs, there was a significant difference in allelic frequency distribution of two SNPs (rs7756935 and rs964184). The allele frequency of rs7756935-C was significantly higher in healthy controls than in CHD cases (17.2 vs. 12.9%; P=0.04, OR=0.72, 95% CI=0.52-0.98). A significant association between rs964184 and CHD was observed in CHD cases compared with non-CHD controls (P=0.04, OR=1.40, 95% CI=1.03-1.90). The HWE test of rs964184 in healthy
controls yielded a P-value of 0.06; therefore, it is possible that an association exists between rs964184 and CHD, compared with healthy controls.

**LD and haplotype test.** We performed an LD test of rs7756935 and rs1805017 of the PLA2G7 gene in CHD cases, non-CHD controls and healthy controls. Our results indicated that the two SNPs were in high, but not complete LD (D'=1.0, r^2<0.05). Since there was a departure from HWE for rs1805017 in males, we only performed an LD test and haplotype test for the two SNPs in females. As shown in Table II, the haplotype rs7756935A-rs1805017G significantly increased the risk of CHD in females (CHD cases vs. non-CHD controls: P=0.04, OR=1.64, 95% CI=1.02-2.65; CHD cases vs. healthy controls: P=0.003, OR=1.88, 95% CI=1.24-2.85).

**Genetic testing under the dominant and recessive inheritance models.** Single SNP analyses for all six SNPs in

---

**Table I. Genotype and allele analysis of the six SNPs.**

| SNPs          | n | Genotype (n) | χ^2 | P-value | HWE | Allele (n) | χ^2 | P-value | OR (95% CI) |
|---------------|---|--------------|-----|---------|-----|------------|-----|---------|-------------|
| rs7528419 (CELSR2) |   | AA AG GG     |     |         |     | A G        |     |         |             |
| CHD cases     | 290| 258 32 0   | 1.00| 0.00    | 548| 32         |     |         |             |
| Non-CHD controls | 198| 178 19 1 1.71| 0.45| 0.43    | 375| 21 0.02   | 0.89| 1.04   | 0.59-1.84  |
| Healthy controls | 331| 288 42 1 1.30| 0.58| 1.00    | 618| 44 0.69   | 0.47| 0.82   | 0.51-1.31  |
| rs7756935 (PLA2G7) |   | AA CA CC    |     |         |     | A C        |     |         |             |
| CHD cases     | 289| 219 65 5   | 1.00| 0.00    | 503| 75         |     |         |             |
| Non-CHD controls | 198| 147 49 2 0.72| 0.73| 0.54    | 343| 53 0.03   | 0.92| 0.97   | 0.66-1.41  |
| Healthy controls | 331| 225 98 8 4.63| 0.10| 0.57    | 548| 114 4.30  | 0.04| 0.72   | 0.52-0.98  |
| rs1805017 (PLA2G7) |   | GG GA CC    |     |         |     | G A        |     |         |             |
| CHD cases     | 288| 198 83 7   | 0.83| 0.73    | 479| 97         |     |         |             |
| Non-CHD controls | 197| 135 49 13 5.60| 0.07| 0.01   | 319| 75 0.77   | 0.40| 0.86   | 0.62-1.20  |
| Healthy controls | 331| 220 103 8 0.39| 0.81| 0.45    | 543| 119 0.28  | 0.66| 0.92   | 0.69-1.24  |
| rs964184 (ZNF259) |   | CC GC GG    |     |         |     | C G        |     |         |             |
| CHD cases     | 290| 156 114 20 | 1.00| 0.00    | 426| 154        |     |         |             |
| Non-CHD controls | 197| 123 67 7 4.78| 0.09| 0.07   | 313| 81 4.60   | 0.04| 1.40   | 1.03-1.90  |
| Healthy controls | 331| 205 103 23 4.73| 0.10| 0.06   | 513| 149 2.74  | 0.10| 1.25   | 0.96-1.61  |
| rs247616 (CETP) |   | CC TC TT    |     |         |     | C T        |     |         |             |
| CHD cases     | 289| 204 74 11 | 0.20| 0.20    | 482| 96         |     |         |             |
| Non-CHD controls | 198| 133 58 7 0.81| 0.66| 0.81   | 324| 72 0.41   | 0.55| 0.90   | 0.64-1.26  |
| Healthy controls | 330| 249 71 10 1.87| 0.40| 0.10   | 569| 91 1.91  | 0.19| 1.25   | 0.91-1.70  |
| rs6511720 (LDLR) |   | GG GT TT    |     |         |     | G T        |     |         |             |
| CHD cases     | 289| 282 7 0   | 1.00| 0.00    | 571| 7          |     |         |             |
| Non-CHD controls | 198| 196 2 0 1.29| 0.31| 1.00    | 394| 2 1.28   | 0.33| 2.42   | 0.50-11.69 |
| Healthy controls | 331| 323 8 0 0.00| 1.00| 1.00    | 654| 8 0.00   | 1.00| 1.00   | 0.36-2.78  |

SNPs, single nucleotide polymorphisms; CHD, coronary heart disease; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval; CETP, cholesteryl ether transfer protein; LDLR, low-density lipoprotein receptor.

**Table II. Estimated haplotypes in female cases and controls.**

| rs7756935 | rs1805017 | CHD cases (n=160) | Non-CHD controls (n=192) | OR (95% CI) | P-value | Healthy controls (n=490) | OR (95% CI) | P-value |
|-----------|-----------|-------------------|--------------------------|-------------|---------|-------------------------|-------------|---------|
| A         | A         | 17 40             | 0.45 (0.25-0.83)         | 0.01        | 82 0.59 | 0.34-1.03              | 0.080       |
| A         | G         | 124 130           | 1.64 (1.02-2.65)         | 0.04        | 317 1.88 | 1.24-2.85              | 0.003       |
| C         | G         | 17 22             | 0.92 (0.47-1.80)         | 0.87        | 91 0.52 | 0.30-0.91              | 0.020       |
| C         | A         | 2 0               | 1.00 (0.34-1.03)         | 0.080       | 82 0.59 | 0.34-1.03              | 0.080       |

CHD, coronary heart disease; OR, odds ratio; CI, confidence interval.
HWE were performed under the dominant and recessive inheritance models. In the dominant model (Table III), significant associations between rs7756935 and rs964184 with CHD were observed between CHD cases and healthy controls. The rs7756935-C allele was a protective factor for CHD (P=0.03, OR=0.68, 95% CI=0.48-0.97) and rs964184-G was a risk factor for CHD (P=0.04, OR=1.40, 95% CI=1.01-1.93). A trend of association between rs964184 and CHD was observed between CHD cases and non-CHD controls (P=0.06, OR=1.43, 95% CI=0.99-1.53). The six SNPs were not significantly associated with CHD in the recessive model (data not shown).
Genetic testing stratified by gender. CHD is the leading cause of mortality worldwide for males and females. However, higher incidences have been observed in males compared with females at all ages and coronary disease occurs up to 10 years later in females (20). Gender issues have received increasing attention in international health policy. Due to the genetic and habitual differences between males and females, we further examined the roles of these SNPs in males and females separately.

In the present study, we performed a gender-stratified analysis to investigate whether gender influences the contribution of SNPs to the risk of CHD. The genotypic and allelic levels are shown in Table IV and V for males and females, respectively.

In the male-stratified samples, rs7528419 of the CELSR2 gene presented a significant association with CHD in CHD cases compared with healthy controls (genotypic, P=0.03; allelic, P=0.04). However, these significant results were not replicated in females (genotypic, P=0.56; allelic, P=0.56), suggesting a gender-dependent effect of rs7528419. In females, rs7756935 of the PL2AG7 gene had a significant association with CHD in CHD cases compared with healthy controls (allelic, P=0.05, OR=0.59, 95% CI=0.35-1.00). The rs1805017 SNP of PL2AG7 had a significant association with CHD in CHD cases compared with non-CHD controls (P=0.03, OR=0.51, 95% CI=0.28-0.93). A tendency of association was observed for rs964184-G of the ZNF259 gene between CHD cases and non-CHD controls (allelic P=0.06, OR=1.60, 95% CI=0.99-2.58). This result was also observed between female CHD cases and female healthy controls (allelic, P=0.05, OR=1.49, 95% CI=1.00-2.22).

Gender-stratified analyses under the dominant and recessive inheritance models. We explored the dominant and recessive inheritance models in male- and female-stratified analyses, respectively. Our results between CHD cases and healthy controls revealed that rs7528419-G is a protective factor for CHD in males (P=0.05, OR=0.49, 95% CI=0.24-0.98). No other significant results were observed in males for the other SNPs (data not shown).

In females (Table VI), rs7756935-C of the PL2AG7 gene had a tendency as a protective factor for CHD in the association test comparing CHD cases and healthy controls (P=0.07, OR=0.59, 95% CI=0.33-1.07). The rs964184-G allele of the ZNF259 gene had a tendency as a risk factor for CHD in the association test comparing CHD cases and non-CHD controls (data not shown).
XU et al.: Lp-PLA\textsubscript{2}-ASSOCIATED POLYMORPHISMS AND CHD

Table VI. Differences in genotype distributions under the dominant and recessive models in females.

|                | CHD cases vs. non-CHD controls | CHD cases vs. healthy controls |
|----------------|--------------------------------|-------------------------------|
|                | OR (95% CI) | P-value | OR (95% CI) | P-value |
| rs7528419 (AG+GG vs. AA) | 1.03 (0.43-2.44) | 1.00 | 1.29 (0.61-2.73) | 0.55 |
| rs7756935 (CA+CC vs. AA) | 1.06 (0.53-2.14) | 1.00 | 0.59 (0.33-1.05) | 0.07 |
| rs1805017 (GG vs. GA+AA) | 0.53 (0.27-1.04) | 0.07 | 0.65 (0.36-1.17) | 0.16 |
| rs964184 (GC+GG vs. CC) | 1.79 (0.98-3.27) | 0.07 | 1.75 (1.05-2.90) | 0.03 |
| rs247616 (TC+TT vs. CC) | 0.96 (0.50-1.82) | 1.00 | 1.23 (0.71-2.15) | 0.48 |
| rs6511720 (GT+TT vs. GG) | 1.85 (0.30-11.36) | 0.66 | 1.87 (0.44-8.01) | 0.41 |

B, Recessive model.

|                | CHD cases vs. non-CHD controls | CHD cases vs. healthy controls |
|----------------|--------------------------------|-------------------------------|
|                | OR (95% CI) | P-value | OR (95% CI) | P-value |
| rs7528419 (GG vs. AG+AA) | - | 0.32 | - | 0.29 |
| rs7756935 (CC vs. CA+AA) | 1.21 (0.23-6.36) | 1.00 | 1.03 (0.20-5.41) | 1.00 |
| rs1805017 (AA vs. GA+GG) | 0.40 (0.13-1.22) | 0.13 | 1.25 (0.25-6.31) | 1.00 |
| rs964184 (GG vs. GC+CC) | 3.23 (0.72-14.61) | 0.16 | 0.88 (0.32-2.40) | 1.00 |
| rs247616 (TT vs. TC+CC) | 1.97 (0.41-9.45) | 0.51 | 1.67 (0.35-8.04) | 0.73 |
| rs6511720 (TT vs. GT+GG) | - | 1.00 | - | 1.00 |

CHD, coronary heart disease; OR, odds ratio; CI, confidence interval.

Table VII. Logistic regression analysis between SNPs and the severity of CHD.

| No. of arteries | Non-CHD controls | rs7528419 | rs7756935 | rs1805017 | rs964184 | rs10846744 | rs247616 | rs6511720 |
|----------------|------------------|-----------|-----------|-----------|----------|------------|----------|-----------|
| Male           | 101              | 0.52      | 0.76      | 0.80      | 0.10     | 0.33       | 0.52     | 0.52      |
| Female         | 97               | 0.79      | 0.83      | 0.04      | 0.17     | 0.46       | 0.73     | 0.91      |
| Total          | 198              | 0.68      | 0.84      | 0.38      | 0.05     | 0.32       | 0.46     | 0.77      |

Bold results represent the number of patients under corresponding conditions, italic results represent P-values. SNPs, single nucleotide polymorphisms; CHD, coronary heart disease.

(P=0.07, OR=1.79, 95% CI=0.98-3.27). This finding was also observed when comparing CHD cases and healthy controls (P=0.03, OR=1.75, 95% CI=1.05-2.90).

Correlation between genotypes and the severity of CHD.

According to the angiographic evidence, CHD cases with ≥50% coronary artery occlusion in one, two and three or more coronary arteries were divided into three respective subgroups. Logistic regression analysis was performed using R statistical software. The P-values indicated the correlation between the severity of CHD and SNPs (Table VII). The rs1805017 SNP of the PLA\textsubscript{2}G7 gene was significantly associated with the severity of CHD in females (P=0.04). In addition, rs964184 of the ZNF259 gene had a marginal association with the severity of CHD (P=0.05).

Discussion

As an inflammatory enzyme expressed in atherosclerotic plaques, Lp-PLA\textsubscript{2} has become a therapeutic target in trials of vascular disease prevention (2). A prospective epidemiological study investigated the associations between circulating Lp-PLA\textsubscript{2} and the risk of vascular diseases (11). Evidence has shown that Lp-PLA\textsubscript{2} is involved in the pathogenesis of atherosclerotic plaque progression (10). It has been regarded as an inflammatory biomarker to predict the risk of stroke and MI (21).
Genetic variations of the Lp-PLA2 gene reduces or eliminates enzyme activity (5). Twenty-five epidemiological studies have established that Lp-PLA2 is a unique vascular-specific biomarker of plaque instability and rupture (10). A meta-analysis of 20,000 patients indicated a high risk for cardiovascular events in patients with high Lp-PLA2 levels (2). In light of the above evidence, we performed a case-control study to investigate the contribution of seven SNPs related to Lp-PLA2, to the risk of CHD.

The rs7528419 SNP of the CELSR2 gene influences the risk of CHD by regulating the level of plasma LDL-C (22). One study demonstrated that CELSR2 gene variants are strongly associated with LDL-C and Lp-PLA2 activity (5). The rs599839 SNP in the vicinity of the PSRC1 and CELSR2 genes may enhance CHD risk by regulating plasma LDL-C level (22). Zhou et al. explored the association of five lipid-associated SNPs with CHD in Chinese individuals (23). The rs599839 SNP in CELSR2-PSRC1-SORT1 is a novel SNP associated with reduced CHD risk in Chinese individuals (OR=0.76, 95% CI=0.61-0.90, P=0.001, in the dominant model) (23). In the present study, we identified rs7528419-G as a protective factor for CHD in the male-stratified association test between the CHD cases and the healthy controls (OR=0.48, 95% CI=0.25-0.93, P=0.04). The association is not supported in females, suggesting an effect of gender in rs7528419. Since the size of the male samples was not large (male CHD cases, n=210; male non-CHD control, n=101; male healthy controls, n=86) in our study, further replication of rs7528419 is warranted.

As the encoding gene of the Lp-PLA2 enzyme, PL2AG7 has been frequently studied and controversy remains in the genetic association between this gene and CHD. A meta-analysis of 12 studies (10,494 cases and 15,624 controls) presented a negative association of PL2AG7 variants with cardiovascular risk factors, coronary atheroma or CHD (24), while several other studies have demonstrated a correlation between PL2AG7 and CHD (25-27). A GeneCard Study identified that PL2AG7 represents an important and potentially functional factor in the pathophysiology of CHD (25). Among the 19 SNPs studied, R92H (rs1805017) and A379V (rs1051931) have become the two most significant SNPs associated with CHD (25). In Chinese individuals, another two PL2AG7 SNPs have been shown to be significantly associated with CHD, including V279F (rs16874954) (26). A379V (rs1051931) has been shown to have a negative association with the risk of CHD in Chinese individuals (26). In a South Korean population, the presence of the 279F allele reduces the risk of CVD (OR=0.64, 95% CI=0.490-0.850, P=0.002). No significant association has been identified between the A379V genotype and CVD risk in South Korean individuals (27). Carriage of the PL2AG7 279F allele causes a natural deficiency in Lp-PLA2 activity and thus has been treated as a protective factor against CHD in Korean males (OR=0.80, 95% CI=0.66-0.97, P=0.02) (28). Since V279F and A379V have been investigated in Chinese individuals (26), the other two SNPs (rs7756935 and rs1805017) of the PL2AG7 gene were investigated in the present study.

The two SNPs (rs7756935 and rs1805017) of the PL2AG7 gene are associated with Lp-PLA2 activity or mass (13); however, there is no direct link between them and CHD. Our association study between the CHD cases and the healthy controls identified that rs7756935 of the PL2AG7 gene is associated with the risk of CHD on the allelic level (OR=0.72, 95% CI=0.52-0.98, P=0.04) and in the dominant model (CA+CC vs. AA, OR=0.68, 95% CI=0.48-0.97, P=0.03). There was no distribution difference among the male subgroups; however, a borderline significant association on the allelic level was observed between the CHD cases and the healthy controls in the female-stratified test (OR=0.59, 95% CI=0.35-1.00, P=0.05). The rs7756935-C allele is regarded as a protective factor for CHD in females, although this finding requires further confirmation.

For the rs1805017 SNP of the PL2AG7 gene, HWE was met in female non-CHD controls; however, this was not the case in male non-CHD controls. The rs1805017-A allele had a significantly different distribution between CHD cases and non-CHD controls in the female-stratified association test (OR=0.51, 95% CI=0.28-0.93, P=0.03). This result is consistent with the findings by Sutton et al. (OR=0.69, 95% CI=0.56-0.85, P<0.001) (25). Logistic regression analysis indicated that rs1805017 may be related to the progressive stages of CHD. In addition, we observed that the haplotype rs1805017A-rs7756935C significantly increases the risk of CHD in females (CHD cases vs. non-CHD controls: P=0.04, OR=1.64, 95% CI=1.02-2.65; CHD cases vs. healthy controls: P=0.003, OR=1.88, 95% CI=1.24-2.85).

The rs964184 SNP of the ZNF259 gene region is near the gene cluster APOA5-APOA4-APOC3-APOAI. The ZNF259 protein strongly increases Lp-PLA2 activity and TG level (29). The rs964184 SNP is associated with HDL-C in subjects with atherogenic dyslipidemia (30). Atherogenic dyslipidemia is a syndrome with a high risk of CHD, characterized by elevated TG, decreased HDL-C and elevated LDL-C (31). A meta-analysis of 8 studies demonstrated that rs964184-G significantly increases the risk of CHD (OR=1.22, 95% CI=1.14-1.30, P=1.2x10^-3) (32). Consistent with previous findings, our results demonstrated that the rs964184-G allele exerts a risk of CHD in Han Chinese individuals. In addition, logistic regression analysis for rs964184 revealed an association with CHD severity (P=0.05).

The SCARB1 gene is a key lipoprotein receptor involved in the reverse cholesterol transport pathway (5). Previous studies demonstrated that the SCARB1 gene is associated with HDL-C levels and thus regulates inflammatory responses (33). A plausible genetic interaction was identified between SCARB1 gene polymorphisms and the risk of CHD in male individuals (34). Another study indicated that SCARB1 null female mice experience accelerated atherosclerosis (33). The rs10846744 SNP of the SCARB1 gene is associated with HDL-C levels (5) and the risk of CHD (13). The rs10846744 SNP of the SCARB1 gene is also associated with atherosclerosis in multiple ethnic populations, including African American (P=0.03), Chinese (P=0.02), European American (P=0.05) and Hispanic populations (P=0.03) (30). The rs10846744-C allele has an association with higher common carotid intimal-medial artery thickness (CCIMT) in Chinese individuals (P=0.02) (30). Our study identified a strong departure from HWE for rs10846744 of the SCARB1 gene (P<0.001). The possible reasons for this phenomenon in our study may be the improperly pair-wise design or the small population size. The subjects in this study originated from Ningbo, China and none of them were related. This SNP is
not further analyzed in this study due to the departure from HWE.

The rs247616 SNP is located on the promoter region of the CETP gene (35), which is associated with the activity of CETP in regulating the metabolism of HDL-C (36). The low concentrations of HDL-C have been regarded as an independent risk factor for cardiovascular disease (9). Increasing the level of HDL-C is under consideration as a secondary therapeutic target for CHD patients (9). In the Whitehall II study, rs247616 was shown to be independently associated with increased HDL-C levels in males (P=9.6E-28) (35). A genome-wide association study (GWAS) revealed that rs247616 of the CETP gene is a quantitative trait locus of HDL level (P=9.7x10^-24) (37). CETP gene variants may affect coronary risk via mechanisms unrelated to HDL-C level (38). In the present study, we were unable to observe a significant association between rs247616 of the CETP gene and CHD (P>0.05). This may be explained by an ethnic difference in the Chinese population or a lack of power in our samples.

The rs6511720 SNP is located on intron 1 of the LDLR gene and is associated with a lower risk of MI (39). LDLR mutations often cause autosomal dominant hypercholesterolemia (ADH) by affecting the hepatic clearance of blood LDL-C (40). Notably, ADH is clinically characterized by high blood LDL-C and atherosclerosis that may eventually lead to CHD (41). The majority of Lp-PLA2 is attached to LDL; however, the known genetic determinants of LDL-C levels, including the LDLR locus, are not significantly associated with CHD. ADH is commonly caused by mutations in the LDLR, apolipoprotein B-100 (APOB) or proprotein convertase subtilisin kexine 9 (PCSK9) genes (42). ADH is characterized by a high concentration of plasma LDL-C and increased risk of premature CHD (40). The association of LDLR and ADH is well studied. We are unable to replicate the correlation between rs6511720 of the LDLR gene and CHD (P>0.05). Further analysis of other LDLR variants is required.

Although a total of 819 Han Chinese individuals were included in our study, it is still not well powered, since the strongest power is 64.3% for rs7756935. The structure of gender in our samples should be adjusted in the future to ensure a more balanced case-control study. All the P-values provided in this study are not corrected by the number of tests, thus there is a chance of false positive results for our study.

In summary, we identified significant associations between four SNPs (rs7528419 of CELSR2, rs7756935 and rs1805017 of PLA2G7 and rs964184 of ZNF259) and CHD in Han Chinese individuals. The rs7528419-G allele reduces the risk of CHD in males. Two SNPs (rs7756935 and rs1805017) in the PLA2G7 gene act as protective factors in females, while rs964184-G is regarded as a risk factor for CHD.

Acknowledgements

This study was supported by the grants from the National Natural Science Foundation of China (No. 31100919 and 30772155), the Qianjiang Scholars Foundation of Zhejiang Province, the Zhejiang Provincial Program for the Cultivation of High level Innovative Health Talents, the Natural Science Foundation of Zhejiang Province (No. Y206608), the Scientific Innovation Team Project of Ningbo (No. 2011B82014), the Youth and Doctor Foundation of Ningbo (No. 2005A610016), the Zhejiang Provincial Natural Science Foundation (No. Y2100240) and the Ningbo Natural Science Foundation (No. 2009A610142). The authors gratefully acknowledge the support of KC Wong Education Foundation, Hong Kong.

References

1. Epp KS and Wilensky RL: Lp-PLA(2)- a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med 269: 90-106, 2011.
2. Rubinstein A and Izikhakov E: Lipoprotein associated phospholipase A2. Harefuah 150: 136-140, 205, 2011 (In Hebrew).
3. Zheng GH, Chen HY, Xiong SQand Chu JF: Lipoprotein-associated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis. Mol Biol Rep 38: 4089–4099, 2011.
4. Ballantyne CM, Hoogeveen RC, Bang H, et al: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109: 837-842, 2004.
5. Suchindran S, Rivedal D, Guyton JR, et al: Genome-wide association study of Lp-PLA2(G) activity and mass in the Framingham Heart Study. PLoS Genet 6: e1000928, 2010.
6. Sandhu MS, Waterworth DM, Debenham SL, et al: LDL-cholesterol concentrations: a genome-wide association study. Lancet 371: 483-491, 2008.
7. Assmann G, Schulte H, von Eckardstein A and Huang Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124: S1-S20, 1996.
8. Gorton T, Castelli WP, Hoyertland MC, Kannel WB and Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707-714, 1977.
9. Lim S, Park YM, Sakuma I and Koh KK: How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol April 12, 2012 (Epub ahead of print).
10. Sertic J, Skoric B, Lovric J, Bozina T and Reiner Z: Does Lp-PLA2 determination help predict atherosclerosis and cardio-cerebrovascular disease? Acta Med Croatica 64: 237-245, 2010 (In Croatian).
11. Thompson A, Gao P, Orfei L, et al: Lipoprotein-associated phospholipase A2(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375: 1536-1544, 2010.
12. Delgado P, Chacón P, Penahua A, et al: Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients. Cerebrovasc Dis 33: 150-158, 2012.
13. Graahlert H, Dupuis J, Bis JC, et al: Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J 33: 238-251, 2012.
14. Higgs ZC, Macafee DA, Braithwaite BD and Maxwell-Armstrong CA: The Seldinger technique: 50 years on. Lancet 666: 1407-1409, 2005.
15. No authors listed: Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 59: 116-128, 1990.
The novel genetic association between lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol 101: 34F–40F, 2008.

Samani NJ, Braund PS, Erdmann J, et al: The novel genetic variant predisposing to coronary artery disease in the region of the PSRC1 and CELSR2 genes on chromosome 1 associates with serum cholesterol. J Mol Med (Berl) 86: 1233-1241, 2008.

Zhou L, Ding H, Zhang X, et al: Genetic variants at newly identified lipid loci are associated with coronary heart disease in a Chinese Han population. PLoS One 6: e27481, 2011.

Casas JP, Nino E, Panayiotou A, et al: PL2AG7 genotype, lipoprotein-associated phospholipase A2 allele, and coronary heart disease risk in 10,494 cases and 15,624 controls of European Ancestry. Circulation 121: 2284-2293, 2010.

Sutton BS, Crosslin DR, Shah SH, et al: Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet 17: 1318-1328, 2008.

Li L, Qi L, Lv N, et al: Association between lipoprotein-associated phospholipase A2 gene polymorphism and coronary artery disease in the Chinese Han population. Ann Hum Genet 75: 605-611, 2011.

Jang Y, Kim OY, Koh SJ, et al: The Val279Phe variant of the LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Atherosclerosis 222: 158-166, 2012.

Smith EN, Chen W, Kahonen M, et al: Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study. PLoS Genet 6: e1001094, 2010.

Borggreve SE, Hilleges HL, Wolfenbuttel BH, et al: An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variants that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 91: 3382-3388, 2006.

Anand SS, Xie C, Pare G, et al: Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study. Circ Cardiovasc Genet 2: 16-25, 2009.

Yang KC, Su YN, Shew JY, et al: LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population. J Formos Med Assoc 106: 799-807, 2007.

Ahmed W, Ajmal M, Sadeque A, et al: Novel and recurrent LDLR gene mutations in Pakistani hypercholesterolemia patients. Mol Biol Rep 39: 7365-7372, 2012.

Slimani A, Jelassi A, Jguirim I, et al: Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Atherosclerosis 222: 158-166, 2012.